Rubicon Research acquires 85% stake in Arinna Lifesciences for ₹175.92 Cr
Rubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences Limited for approximately ₹175.92 Crores in cash. Arinna, a branded pharmaceutical marketing company headquartered in Ahmedabad, specializes in the CNS/neuro-psychiatric therapeutic segment in the Indian domestic market. Arinna reported a turnover of ₹71.5 crores for FYE March 2025. This acquisition aligns with Rubicon's strategy to leverage its IP and chronic products portfolio, particularly in the CNS category, and gain access to Arinna's established sales and distribution network in India for its differentiated offerings. The transaction values Arinna at an enterprise value of ₹200 Crores and is expected to be completed within one month.
Key Highlights
- Rubicon Research acquires 85% stake in Arinna Lifesciences for ₹175.92 Cr cash.
- Arinna, a CNS-focused pharma marketer, had ₹71.5 Cr turnover in FY25.
- Acquisition expands Rubicon's presence in India's CNS therapeutic market.
- Arinna's sales network provides access for Rubicon's specialty products.
- The deal is expected to close within one month.